Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
genentech
9
×
life sciences
national blog main
national top stories
new york blog main
9
×
san francisco blog main
biotech
new york top stories
san diego blog main
san diego top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
bristol-myers squibb
cancer
deals
eli lilly
fda
pfizer
clinical trials
ipo
johnson & johnson
startups
cancer immunotherapy
What
bio
roundup
drug
news
approved
big
biotech
cancer
companies
drugs
fda
group
known
liver
medical
new
pharmaceutical
today
acquire
adu
agreed
aiming
alzheimer’s
ambys
annual
appetite
august
beats
bids
billion
biogen
biopharma
black
bread
breast
broad
busy
butter
buyout
cancer's
Language
unset
Current search:
genentech
×
" new york blog main "
×
" boston top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine